CYBIN INC. (HELP) Form 6-K — Jul 21, 2026
Helus Pharma (Cybin Inc.) has completed enrollment in its Phase 3 APPROACH study evaluating HLP003 for the adjunctive treatment of Major Depressive Disorder. The trial successfully enrolled 223 participants ahead of schedule, marking a significant de-risking event for the company's lead therapeutic program. The company expects to report topline data from the APPROACH study in the fourth quarter of 2026. HLP003, an investigational deuterated psilocin analogue, previously received FDA Breakthrough Therapy Designation based on Phase 2 data showing durable efficacy and high remission rates.
Key figures
- Participants enrolled
- 223
- Phase 2 madrs reduction
- ~23 points
- Competitor sales q2 2026 usd
- $584 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.